# Advancements in Targeting Biofilm-Associated Infections: Novel Therapeutic Approaches and Challenges

**V. Thiruloga Chandran[1], M, Thangaraj[2], T. Gnanakumar[3] and J. Suriakumar[4]***

[1]*Associate Professor, Department of General Surgery, Government Medical College, Dindigul, Tamil Nadu, India.*
[2]*Associate Professor, Department of Medicine, Government Medical College, Dindigul, Tamil Nadu, India.*
[3]*Associate Professor, Department of General Surgery, Government Medical College, Ramanathapuram, Tamil Nadu, India.*
[4*]*Associate Professor, Department of Microbiology, Government Medical College, Dindigul, Tamil Nadu, India.*

***Corresponding author:** J. Suriakumar*
**Associate Professor, Department of Microbiology, Government Medical College, Dindigul, Tamil Nadu, India.*

**KEYWORDS**
Biofilm formation, Chronic infections, Antimicrobial resistance, Quorum sensing, Therapeutic strategies

**ABSTRACT**
Biofilm development is a prevalent process where microbial colonies attach to surfaces and generate an extracellular matrix, leading to the genesis of persistent infections. Biofilms in clinical settings are associated with chronic infections that are difficult to cure due to their resistance to both antimicrobial drugs and host immune responses. This review investigates the phases and molecular mechanisms of biofilm development, focusing on the factors that promote the survival of biofilm-associated bacteria. It investigates the role of biofilms in chronic infections including cystic fibrosis, endocarditis, chronic sinusitis, and implant infections. Additionally, it examines the underlying processes of biofilm resistance to antibiotics, including slower diffusion of antimicrobial drugs, altered bacterial physiology, gene expression alterations, and quorum sensing. The review also considers options for combating biofilm-related infections, such as inhibiting biofilm formation, enzymatic destruction of the biofilm matrix, bacteriophage therapy, nanoparticle usage, antibiotic combinations, and host immunological modulation. Understanding biofilm formation and its implications in chronic infections is critical for developing effective therapies to prevent and treat biofilm-associated infections.

## Introduction

Biofilms are structured communities of microorganisms that grow on both living and non-living surfaces and are enclosed in an extracellular matrix that they manufacture themselves. This type of bacterial proliferation is not only common in nature, but it also contributes significantly to chronic infections in clinical settings [1]. Pathogens in biofilms have distinct features that render them significantly more resistant to drugs and host immunological responses than their planktonic (free-floating) cousins. This increased resistance causes persistent, recurrent infections that are difficult to treat with standard medicines [2]. Infections caused by biofilm formation have been linked to a variety of illnesses, including cystic fibrosis, infective endocarditis, chronic sinusitis, urinary tract infections, and infections from implanted medical devices such as prosthetic joints and catheters. In many cases, biofilms operate as a protective barrier, sheltering bacteria from antimicrobial agents and immune cells, complicating treatment of infections [3]. Biofilm infections have been associated to a wide range of disorders, including cystic fibrosis, infective endocarditis, chronic sinusitis, urinary tract infections, and infections from implanted medical devices such as prosthetic joints and catheters. Biofilms often behave as a protective barrier, shielding bacteria from antimicrobial agents and immune cells, complicating infection therapy [4]. Understanding the molecular mechanisms that drive biofilm formation and their function in chronic infections is critical for finding novel approaches to preventing, managing, and treating these difficult illnesses [5]. This review will look at the production of biofilms, their clinical importance, and current treatments for combating biofilm-associated infections.

**Biofilm Formation: Mechanisms and Stages**

Biofilm formation is a multi-stage process that allows microorganisms to colonize surfaces and survive in a protected habitat. This process is critical to the persistence and duration of infections produced by biofilm-forming bacteria [6]. Biofilm production has important clinical consequences since biofilm-associated illnesses are frequently resistant to conventional antibiotics and are linked to long-term health issues [7]. This section will explore more into the stages of biofilm formation and the elements that influence its growth and persistence.

**1. Initial Attachment**

Biofilm production starts with the adhesion of free-floating (planktonic) microorganisms to a surface. This is usually a reversible contact facilitated by weak forces such van der Waals forces, electrostatic interactions, or hydrophobic effects. Bacteria may first adhere weakly to the surface, which can be readily dislodged. However, this is a key first step in biofilm creation because it lays the groundwork for future colonization [8]. Bacteria create surface features such as adhesins and fimbriae after first adhesion. These are specific proteins that assist bacteria in establishing a stronger attachment to the surface. Adhesins bind to certain receptors on the surface or in host tissues to reinforce the attachment. Fimbriae, which are hair-like appendages, let bacteria adhere more securely to surfaces [9]. Environmental factors such as surface nature, the availability of extracellular matrix components, and the bacterial strain's ability to create specific adhesion factors can all have an impact on this early attachment phase. Once the bacteria have successfully adhered to the surface, they are ready for the next stage of biofilm production [10].

**2. Irreversible Attachment**

Following the initial connection, bacteria start producing extracellular polymeric substances (EPS), which comprise polysaccharides, proteins, and extracellular DNA. The EPS matrix works as a glue, securing the bacteria to the surface and enclosing them in a protective matrix. As the matrix grows, the attachment becomes irreversible, and the bacteria are embedded in a dense, self-produced network that provides further protection against external threats such as host immune cells and antimicrobials [11]. The EPS matrix serves several functions in biofilm formation. It not only helps anchor bacteria to the surface but also facilitates the establishment of microcolonies. The components of the EPS matrix, particularly polysaccharides, provide structural integrity to the biofilm, while extracellular DNA can contribute to the stability of the biofilm by linking bacteria together. This irreversible attachment phase is critical for the progression of biofilm development, as it allows for the formation of complex bacterial communities that can grow and spread in a controlled, protected environment [12].

**3. Maturation:**

Once bacteria have established a stable attachment and formed microcolonies, the biofilm enters the maturation phase. During this phase, the biofilm grows and becomes more complex. The bacteria within the biofilm divide and produce additional EPS, expanding the structure and allowing it to reach greater thickness [13]. The biofilm develops a three-dimensional architecture, with channels and cavities that allow for the exchange of nutrients, gases, and waste products. These channels facilitate the diffusion of essential nutrients and the removal of waste products, which is important for maintaining the metabolic activity of bacteria in the biofilm [14]. The maturation phase is marked by significant phenotypic changes in the bacteria. Bacteria in biofilms often exhibit altered gene expression compared to their planktonic counterparts. These changes may include the upregulation of genes involved in the synthesis of EPS, antibiotic resistance, and the regulation of virulence factors [15]. For example, bacteria in biofilms may alter their metabolism, slowing down growth rates or entering a dormant state, which makes them less susceptible to antimicrobial agents that target actively dividing cells. Additionally, biofilm bacteria often exhibit resistance to host immune responses, such as phagocytosis, due to the protective barrier created by the EPS matrix [16].

The maturation phase is crucial in determining the long-term persistence of biofilm-associated illnesses. The structural intricacy of the biofilm, as well as phenotypic changes in the bacteria, contribute to its tenacity, making infections difficult to eliminate. This resistance presents a significant difficulty in treating persistent biofilm-related infections, as traditional antibiotic regimens are frequently ineffective against mature biofilms [17].

**4. Dispersion**

The ultimate stage of biofilm production is dispersion, in which biofilm components are dispersed as planktonic bacteria. These bacteria are now free to travel to new surfaces or tissues, allowing for increased colonization and adding to the infection's chronic character [18]. Dispersion is a dynamic phenomenon that can happen in reaction to environmental changes including nutritional depletion, oxidative stress, or the presence of antimicrobial drugs. Bacteria in the biofilm may detect these signals using quorum sensing processes, causing the discharge of planktonic cells to ensure the infection's survival and spread [19]. Dispersion is a critical mechanism for the persistence of biofilm-associated infections. When biofilms grow too large or resources inside the biofilm are depleted, dispersion permits bacteria to travel and colonize other locations, maintaining the infection cycle. This ability to disseminate and colonize new places is critical to the long-term persistence of biofilm-related illnesses because it allows bacteria to elude immune monitoring and adapt to different microenvironments [20]. This table 1 illustrates the mechanisms behind each stage of biofilm formation and ties them to the clinical significance, emphasizing the challenges biofilms pose in chronic infections and medical device-related infections.

**Table: 1 Stages of biofilm formation along with key mechanisms and clinical relevance**

| Stage | Mechanisms Involved | Clinical Relevance |
|---|---|---|
| Initial Attachment | - Planktonic bacteria encounter a surface.<br>- Reversible weak interactions (hydrophobic, electrostatic). | - Initiates biofilm formation on abiotic or biotic surfaces (e.g., tissue, implants).<br>- Critical step in chronic infection development [21]. |
| Irreversible Attachment | - Production of surface adhesins or fimbriae.<br>- Extracellular polymeric substances (EPS) are produced. | - Strong attachment to host tissues or devices like catheters and prosthetics.<br>- Forms the foundation for biofilm stability [22]. |
| Maturation | - Bacteria proliferate, forming microcolonies.<br>- EPS matrix becomes more complex, creating channels. | - Biofilm structure enhances bacterial survival.<br>- Increased resistance to immune clearance and antibiotic treatment [23]. |
| Dispersion | - Biofilm cells are released as planktonic bacteria to colonize new sites.<br>- Genetic and environmental cues trigger dispersal. | - Leads to the spread of infection to distant tissues or organs.<br>- Contributes to the persistence and recurrence of chronic infections [24]. |

**The biofilm matrix and its resistance to environmental stressors**

The biofilm matrix protects microorganisms from a variety of environmental stresses. This matrix acts as a physical barrier to antimicrobial agents, restricting their ability to penetrate the biofilm and reach the bacteria contained therein. Furthermore, the matrix protects against host immunological reactions, such as phagocytosis, by preventing immune cells from contacting the bacteria [25]. The biofilm's distinct structure, combined with physiological changes in bacteria, produces a microenvironment that promotes bacterial survival and proliferation, even in the face of antimicrobial therapies [26]. Biofilm-associated bacteria are remarkably resilient, making illnesses difficult to cure. The matrix not only acts as a physical barrier, but it also helps bacteria resist drugs, immunological

reactions, and other stressors by altering gene expression. This ability to survive in unfavourable surroundings is a distinguishing feature of biofilm-related infections, making them especially difficult to treat in clinical settings [27].

**Role of Biofilms in Chronic Infections**

Biofilm formation plays a crucial role in the persistence of several chronic and recalcitrant infections. In these infections, biofilms protect microorganisms from both the immune system and antimicrobial treatments, making them particularly difficult to treat. The following sections explore how biofilm formation contributes to the persistence of infections in various clinical scenarios [28].

**Cystic Fibrosis (CF)**

Bacterial infections like Pseudomonas aeruginosa typically invade the lungs. These bacteria frequently form biofilms on the epithelial cells that line the respiratory tract. The biofilm protects the bacteria from host immunological responses and antimicrobial treatments. This causes chronic lung infections, which are a defining feature of CF, resulting in progressive lung damage, inflammation, and respiratory failure. The thick, sticky mucus found in CF patients exacerbates biofilm development, producing an environment favorable to bacterial persistence. Biofilm production in CF can also make it difficult to treat these infections since it protects the bacteria from antibiotics, rendering standard therapies ineffective [29].

**Endocarditis**

Infective endocarditis, an infection of the heart valves, is another significant clinical setting in which biofilms play an important role. Bacteria like Staphylococcus aureus and Streptococcus viridans can build biofilms on heart valves, making it difficult to cure. The biofilm matrix shields the bacterium from both human immune systems and drugs, forming a permanent reservoir for the bacteria that can cause repeated infections [30]. The biofilm-protected state adds to the high death rate associated with infective endocarditis. Even with antibiotics, the bacteria in the biofilm are difficult to eliminate, necessitating long-term or intensive treatment. The biofilm complicates treatment and raises the risk of consequences such septic emboli, heart valve damage, and systemic infection [31].

**Chronic Sinusitis**

In chronic sinusitis, biofilm formation can lead to infection persistence and recurrence. Staphylococcus aureus and Pseudomonas aeruginosa are common infections associated with chronic sinusitis. These bacteria can create biofilms in the sinuses, complicating conventional therapeutic methods. Standard therapy, such as antibiotics and surgery, may be ineffective in removing the biofilm because the bacteria within are protected from the effects of treatment by the biofilm matrix. This biofilm-associated protection causes persistent inflammation, nasal congestion, facial pain, and recurrent infections, all of which have a negative impact on patients' quality of life. The biofilm also inhibits normal sinus function, resulting in extended discomfort and consequences [32].

**Implant Infections**

Biofilm accumulation on medical equipment, including prosthetic joints, heart valves, and catheters, can lead to recurrent infections in patients. Pathogens such as Staphylococcus epidermidis, Enterococcus faecalis, and Pseudomonas aeruginosa can attach to and form biofilms on the surfaces of these alien materials [33]. The biofilm shields the bacteria from the host's immune system and antibiotic medicines, making these infections very difficult to cure. To effectively treat biofilm-associated infections on implants, device removal is often required. For example, biofilm growth on prosthetic joints can result in persistent infections that persist after lengthy antibiotic treatment. These infections frequently cause serious problems, including device failure, joint damage, and the need for surgical intervention [34]. This table 2 highlights how biofilms contribute to the persistence and recurrence of infections in different clinical settings

**Table:2 The role of biofilms in chronic infections**

| Infection Type | Biofilm Formation Location | Key Pathogen(s) | Impact of Biofilm |
|---|---|---|---|
| Cystic Fibrosis (CF) | Lungs, particularly epithelial cells | *Pseudomonas aeruginosa*, *Staphylococcus aureus* | - Biofilm protects bacteria from immune responses and antibiotics.<br>- Chronic lung infections, inflammation, and tissue damage.<br>- Thick mucus in CF patients facilitates biofilm formation [35]. |
| Endocarditis | Heart valves | *Staphylococcus aureus*, *Streptococcus viridans* | - Biofilm formation on heart valves creates a persistent infection.<br>- High mortality rates due to difficulty in eradicating biofilms.<br>- Reservoir for ongoing infection even during antibiotic treatment [36]. |
| Chronic Sinusitis | Sinuses | *Staphylococcus aureus*, *Pseudomonas aeruginosa* | - Biofilm contributes to chronic inflammation.<br>- Recurrent infections, making standard treatments less effective [37]. |
| Implant Infections | Medical devices (e.g., prosthetic joints, catheters) | *Staphylococcus epidermidis*, *Enterococcus faecalis* | - Biofilm formation on implants leads to persistent infections.<br>- Often requires device removal for resolution [38]. |

**Biofilm Resistance to Antimicrobial Agents**

Biofilm-associated illnesses are notoriously difficult to cure due to the increased resistance that biofilms confer on bacteria. This resistance is caused by a combination of mechanisms that protect bacterial cells within the biofilm from the effects of antimicrobial drugs, resulting in chronic infections that are more difficult to eliminate [39]. The following are the primary pathways that contribute to increased antibiotic resistance in biofilm-associated infections:

**1. Reduced Antibiotic Diffusion**

The biofilm matrix, made up of EPS, functions as a physical barrier, limiting antibiotic penetration. The EPS matrix is a complex mixture of polysaccharides, proteins, and extracellular DNA that efficiently traps antimicrobial drugs and prevents their penetration into the biofilm's deeper layers. This barrier inhibits antibiotics from reaching the bacterial cells entrenched in the biofilm, allowing them to live and multiply despite antibiotic therapy. The physical form of the biofilm thus plays a significant role in the lowered efficiency of antimicrobial treatments [40].

**2. Microbial Physiology**

Bacteria in biofilms have different physiological states than their planktonic cousins. One notable change is a shift in metabolic activity. Many bacteria in biofilms become latent or slow-growing, making them less vulnerable to drugs that target actively dividing cells. Antibiotics, such β-lactams, are more effective against rapidly dividing bacteria. However, biofilm bacteria have a slower growth rate, limiting their capacity to kill or suppress pathogens. Furthermore, the microenvironment within the biofilm frequently produces gradients of oxygen, pH, and nutrients, resulting in places where bacterial cells may be in a state of metabolic dormancy, boosting their survival against antimicrobial drugs [41].

**3. variations in Gene Expression**

Antibiotic resistance is linked to variations in gene expression among bacteria within biofilms. This includes upregulating resistance genes and activating stress response pathways. For example, bacteria in biofilms may develop efflux pumps, which actively pump antibiotics out of the bacterial cell, lowering the drug's intracellular concentration and rendering it ineffective. Biofilm-associated bacteria can create enzymes that breakdown or modify antimicrobial drugs, including β-lactamases, which break down β-lactam antibiotics. These genetic changes help bacteria in biofilms survive in the presence of otherwise potent drugs [42].

**4. Quorum Sensing**

Bacteria use quorum sensing, a cell-to-cell communication system, to coordinate gene expression by population density. Bacteria in biofilms interact by releasing signaling molecules known as autoinducers. This technique enables bacteria to coordinate their activity, such as biofilm formation, gene expression, and antibiotic resistance mechanisms. Quorum sensing is crucial for biofilm stability and resistance because it affects the expression of genes involved in biofilm formation, virulence, and antibiotic resistance. For example, quorum sensing can activate the creation of extracellular matrix components that shield bacteria from antibiotics or induce the development of resistance mechanisms such as efflux pumps and antibiotic-degrading enzymes [43].

**Strategies for Disrupting Biofilm-Related Infections**

Combating biofilm-related diseases necessitates a multidisciplinary approach, as biofilms are resilient and difficult to treat with standard antibiotics. To address this, researchers and physicians have investigated a variety of ways for preventing biofilm formation, eliminating established biofilms, and increasing the efficacy of antimicrobial medicines. These techniques target several stages of the biofilm lifecycle, from early creation to maintenance and persistence [44]. The following are some significant strategies being studied to combat biofilm-related infections:

**1. Disrupting Biofilm development**

Preventing biofilm development is a successful technique for reducing biofilm-related illnesses. This can be accomplished by targeting the molecular pathways that allow bacteria to cling to surfaces and build the extracellular matrix that forms the biofilm. One technique is to inhibit the creation of adhesins, which are surface proteins or pili that allow bacteria to first connect to surfaces. By interfering with these adhesion factors, bacteria are less likely to form a biofilm [45]. In addition, suppressing quorum sensing, the process by which bacteria communicate to coordinate biofilm formation and other actions, can hinder biofilm development. Molecules that impair quorum sensing, such as furanones or synthetic analogs, have showed potential in inhibiting biofilm development by interfering with bacterial communication channels [46].

**2. Enzymatic Degradation of Biofilm Matrix**

Enzymatic degradation of the biofilm matrix is a well-studied strategy for eradicating biofilms. The matrix, which is made up of polysaccharides, proteins, and extracellular DNA, provides structural support for the biofilm while also protecting bacteria from drugs and immunological reactions. DNases, proteases, and polysaccharide-degrading enzymes can destabilize biofilm stability and increase antibiotic penetration. For example, a mucolytic drug called N-acetylcysteine (NAC) has been utilized to dissolve Pseudomonas aeruginosa biofilms in cystic fibrosis patients. These enzymatic treatments weaken the matrix, making biofilm-associated bacteria more susceptible to antimicrobial drugs and immunological clearance [47].

**3. Bacteriophage Therapy**

Viruses called phages invade and kill bacteria. They have been presented as a possible therapeutic for targeting biofilm-associated bacteria while preserving the host's beneficial microbiota. Phage treatment has significant advantages over traditional antibiotics, including the ability to directly target biofilm-forming bacteria and penetrate biofilm matrices. Phages can evolve alongside bacterial

resistance, making them a viable alternative or supplement to antibiotic therapy. Researchers are currently looking into phage-based formulations for treating chronic biofilm infections including Pseudomonas aeruginosa in cystic fibrosis patients and Staphylococcus aureus in implant-related infections [48].

**4. Nanoparticles**

Nanoparticles manufactured from silver or gold have antibacterial characteristics and are being studied for their potential to disrupt biofilms. Nanoparticles can penetrate the biofilm matrix more efficiently than larger molecules, allowing them to reach bacterial cells that would otherwise be resistant to antibiotics [49]. Silver nanoparticles, for example, have been demonstrated to have potent antibacterial activity against biofilm-forming bacteria including Staphylococcus epidermidis and Pseudomonas aeruginosa. Nanoparticles can also be made to interact with bacterial cells, either directly or as delivery vehicles for antimicrobial medicines. Their ability to increase the efficiency of antibiotics makes them a promising tool in the fight against biofilm-related infections [50].

**5. Antibiotic Combinations**

Combining antibiotics is an effective way to overcome biofilm resistance. Combining antibiotics that target diverse elements of bacterial physiology, such as those that breakdown the biofilm matrix, can improve therapy success. Combining β-lactam antibiotics that target cell wall production with DNase that breaks down the biofilm matrix improves antibiotic penetration and efficacy against biofilm-associated bacteria [51]. Other combination tactics include combining antibiotics with antimicrobial peptides or metal ions, which can degrade the biofilm structure and improve antibiotic action. Combination medicines treat biofilm-related infections more comprehensively because they target biofilm production and bacterial growth at the same time [52].

**6. Host Immune Modulation:**

Modulating the human immune response to remove biofilm-associated bacteria is a potential method. The immune system's capacity to recognize and eliminate biofilm germs is frequently hampered by the biofilm's protective matrix. Improving neutrophil recruitment to biofilm sites or increasing the host's generation of antibodies that particularly target biofilm bacteria could assist overcome this barrier [53]. Immunomodulatory drugs, such as cytokines and immune-stimulating substances, are being investigated for their capacity to improve biofilm clearance by the host immune system. In addition, treatments that increase biofilm bacterium detection and phagocytosis could supplement antibiotic treatment, providing a diverse approach to persistent infection resolution [54].

**Conclusion**

Biofilm production is critical in the pathophysiology of chronic infections, influencing the persistence and recurrence of infections in illnesses such as cystic fibrosis, endocarditis, and prosthetic device-related infections. Biofilms' innate resilience to both antibiotics and human immune responses creates considerable hurdles in treating these illnesses. Understanding the mechanisms behind biofilm formation and the factors that contribute to biofilm-associated antibiotic resistance lays the groundwork for the development of innovative treatment techniques. Disrupting biofilm formation, increasing the efficacy of antimicrobial medicines, and utilizing alternative therapies such as bacteriophages and nanoparticles are all viable paths for tackling chronic biofilm-associated infections in the future.

**Funding**

None

**Conflict of Interest**

The authors report no conflicts of interest in this work.

**References**

1. Wang C, Su Y, Shahriar SS, Li Y, Xie J. Emerging strategies for treating medical device and wound-associated biofilm infections. Microbial Biotechnology. 2024 Oct;17(10):e70035.
2. Javanmard Z, Pourhajibagher M, Bahador A. Advancing anti-biofilm strategies: Innovations to combat biofilm-related challenges and enhance efficacy. Journal of Basic Microbiology. 2024 Dec;64(12):e2400271.
3. Khardori N, Yassien M. Biofilms in device-related infections. Journal of industrial microbiology and biotechnology. 1995 Sep 1;15(3):141-7.
4. Chee E, García AJ. Biomaterial therapeutic strategies for treatment of bacterial lung infections. Biofilm. 2023 Dec 1;5:100111.
5. Costerton W, Veeh R, Shirtliff M, Pasmore M, Post C, Ehrlich G. The application of biofilm science to the study and control of chronic bacterial infections. The Journal of clinical investigation. 2003 Nov 15;112(10):1466-77.
6. Li P, Yin R, Cheng J, Lin J. Bacterial biofilm formation on biomaterials and approaches to its treatment and prevention. International Journal of Molecular Sciences. 2023 Jul 20;24(14):11680.
7. Mirghani R, Saba T, Khaliq H, Mitchell J, Do L, Chambi L, Diaz K, Kennedy T, Alkassab K, Huynh T, Elmi M. Biofilms: Formation, drug resistance and alternatives to conventional approaches. AIMS microbiology. 2022 Jul 4;8(3):239.
8. Chao Y, Zhang T. Surface-enhanced Raman scattering (SERS) revealing chemical variation during biofilm formation: from initial attachment to mature biofilm. Analytical and bioanalytical chemistry. 2012 Sep;404:1465-75.
9. Davies PL, Guo S. Structures of Fibrillar Adhesins That Mediate Bacteria–Host Interactions and Biofilm Formation. InBiofilm Matrix 2024 Nov 19 (pp. 153-185). Cham: Springer Nature Switzerland.
10. Pavithra D, Doble M. Biofilm formation, bacterial adhesion and host response on polymeric implants—issues and prevention. Biomedical Materials. 2008 Aug 8;3(3):034003.
11. Starkey M, Gray KA, Chang SI, Parsek MR. A sticky business: the extracellular polymeric substance matrix of bacterial biofilms. Microbial biofilms. 2004 Jun 16:174-91.
12. Gupta P, Pruthi PA, Pruthi V. Role of exopolysaccharides in biofilm formation. InIntroduction to biofilm engineering 2019 (pp. 17-57). American Chemical Society.
13. Serra DO, Hengge R. Stress responses go three dimensional–the spatial order of physiological differentiation in bacterial macrocolony biofilms. Environmental microbiology. 2014 Jun;16(6):1455-71.
14. Billings N, Birjiniuk A, Samad TS, Doyle PS, Ribbeck K. Material properties of biofilms—a review of methods for understanding permeability and mechanics. Reports on Progress in Physics. 2015 Feb 26;78(3):036601.
15. Jolivet-Gougeon A, Bonnaure-Mallet M. Biofilms as a mechanism of bacterial resistance. Drug Discovery Today: Technologies. 2014 Mar 1;11:49-56.
16. Singh S, Datta S, Narayanan KB, Rajnish KN. Bacterial exo-polysaccharides in biofilms: role in antimicrobial resistance and treatments. Journal of Genetic Engineering and Biotechnology. 2021 Dec;19:1-9.
17. Rather MA, Gupta K, Mandal M. Microbial biofilm: formation, architecture, antibiotic resistance, and control strategies. Brazilian Journal of Microbiology. 2021 Dec 1:1-8.
18. Kaplan JÁ. Biofilm dispersal: mechanisms, clinical implications, and potential therapeutic uses. Journal of dental research. 2010 Mar;89(3):205-18.
19. Mishra S, Gupta A, Upadhye V, Singh SC, Sinha RP, Häder DP. Therapeutic strategies against biofilm infections. Life. 2023 Jan 6;13(1):172.
20. Sharma S, Mohler J, Mahajan SD, Schwartz SA, Bruggemann L, Aalinkeel R. Microbial biofilm: a review on formation, infection, antibiotic resistance, control measures, and innovative treatment. Microorganisms. 2023 Jun 19;11(6):1614.

21. Lappin-Scott HM, Bass C. Biofilm formation: attachment, growth, and detachment of microbes from surfaces. American journal of infection control. 2001 Aug 1;29(4):250-1.
22. Hinsa SM, Espinosa-Urgel M, Ramos JL, O'Toole GA. Transition from reversible to irreversible attachment during biofilm formation by Pseudomonas fluorescens WCS365 requires an ABC transporter and a large secreted protein. Molecular microbiology. 2003 Aug;49(4):905-18.
23. Liaqat I, Liaqat M, Ali S, Ali NM, Haneef U, Mirza SA, Tahir HM. Biofilm formation, maturation and prevention: a review. J Bacteriol Mycol. 2019 Jan 15;6(1):1092.
24. Rumbaugh KP, Sauer K. Biofilm dispersion. Nature Reviews Microbiology. 2020 Oct;18(10):571-86.
25. Flemming HC, Wingender J. The biofilm matrix. Nature reviews microbiology. 2010 Sep;8(9):623-33.
26. Sharma S, Mohler J, Mahajan SD, Schwartz SA, Bruggemann L, Aalinkeel R. Microbial biofilm: a review on formation, infection, antibiotic resistance, control measures, and innovative treatment. Microorganisms. 2023 Jun 19;11(6):1614.
27. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clinical microbiology reviews. 2002 Apr;15(2):167-93.
28. Bjarnsholt T. The role of bacterial biofilms in chronic infections. Apmis. 2013 May;121:1-58.
29. Moreau-Marquis S, Stanton BA, O'Toole GA. Pseudomonas aeruginosa biofilm formation in the cystic fibrosis airway. Pulmonary pharmacology & therapeutics. 2008 Aug 1;21(4):595-9.
30. Lerche CJ, Schwartz F, Theut M, Fosbøl EL, Iversen K, Bundgaard H, Høiby N, Moser C. Anti-biofilm approach in infective endocarditis exposes new treatment strategies for improved outcome. Frontiers in cell and developmental biology. 2021 Jun 18;9:643335.
31. Su Y, Yrastorza JT, Matis M, Cusick J, Zhao S, Wang G, Xie J. Biofilms: formation, research models, potential targets, and methods for prevention and treatment. Advanced Science. 2022 Oct;9(29):2203291.
32. Bendouah Z, Barbeau J, Hamad WA, Desrosiers M. Biofilm formation by Staphylococcus aureus and Pseudomonas aeruginosa is associated with an unfavorable evolution after surgery for chronic sinusitis and nasal polyposis. Otolaryngology—Head and Neck Surgery. 2006 Jun;134(6):991-6.
33. Arciola CR, Campoccia D, Montanaro L. Implant infections: adhesion, biofilm formation and immune evasion. Nature reviews microbiology. 2018 Jul;16(7):397-409.
34. Kumar A, Alam A, Rani M, Ehtesham NZ, Hasnain SE. Biofilms: Survival and defense strategy for pathogens. International Journal of Medical Microbiology. 2017 Dec 1;307(8):481-9.
35. H∅ iby N, Ciofu O, Bjarnsholt T. Pseudomonas aeruginosa biofilms in cystic fibrosis. Future microbiology. 2010 Nov 1;5(11):1663-74.
36. Kaushik A, Kest H, Sood M, Thieman C, Steussy BW, Padomek M, Gupta S. Infective Endocarditis by Biofilm-Producing Methicillin-Resistant Staphylococcus aureus—Pathogenesis, Diagnosis, and Management. Antibiotics. 2024 Nov 25;13(12):1132.
37. Cryer J, Schipor I, Perloff JR, Palmer JN. Evidence of bacterial biofilms in human chronic sinusitis. Orl. 2004 Aug 19;66(3):155-8.
38. Shirtliff M, Leid JG, Shirtliff M. The role of biofilms in device-related infections. Berlin: Springer; 2009.
39. Mah TF, O'Toole GA. Mechanisms of biofilm resistance to antimicrobial agents. Trends in microbiology. 2001 Jan 1;9(1):34-9.
40. Stewart PS. Mechanisms of antibiotic resistance in bacterial biofilms. International journal of medical microbiology. 2002 Jan 1;292(2):107-13.
41. Saha A, Arora K, Sajid A, Arora G. Cellular signaling in bacterial biofilms. Implication of Quorum Sensing System in Biofilm Formation and Virulence. 2018:81-109.
42. Beloin C, Ghigo JM. Finding gene-expression patterns in bacterial biofilms. Trends in microbiology. 2005 Jan 1;13(1):16-9.
43. Li YH, Tian X. Quorum sensing and bacterial social interactions in biofilms. Sensors. 2012 Feb 23;12(3):2519-38.

44. Vuotto C, Donelli G. Novel treatment strategies for biofilm-based infections. Drugs. 2019 Oct;79:1635-55.
45. Kostakioti M, Hadjifrangiskou M, Hultgren SJ. Bacterial biofilms: development, dispersal, and therapeutic strategies in the dawn of the postantibiotic era. Cold Spring Harbor perspectives in medicine. 2013 Apr 1;3(4):a010306.
46. Xu Y, Wang Y, Ding X, Wang J, Zhan X. Inhibitory effects of reuterin on biofilm formation, quorum sensing and virulence genes of Clostridium perfringens. Lwt. 2022 Jun 1;162:113421.
47. Watters CM, Burton T, Kirui DK, Millenbaugh NJ. Enzymatic degradation of in vitro Staphylococcus aureus biofilms supplemented with human plasma. Infection and drug resistance. 2016 Apr 27:71-8.
48. Chegini Z, Khoshbayan A, Taati Moghadam M, Farahani I, Jazireian P, Shariati A. Bacteriophage therapy against Pseudomonas aeruginosa biofilms: a review. Annals of clinical microbiology and antimicrobials. 2020 Dec;19:1-7.
49. Su C, Huang K, Li HH, Lu YG, Zheng DL. Antibacterial properties of functionalized gold nanoparticles and their application in oral biology. Journal of Nanomaterials. 2020;2020(1):5616379.
50. El-Shennawy G, Abd Ellatif R, Badran S, El-Sokkary R. Silver nanoparticles: a potential antibacterial and antibiofilm agent against biofilm forming multidrug resistant bacteria. Microbes and Infectious Diseases. 2020 Aug 1;1(2):77-85.
51. Singh A, Amod A, Pandey P, Bose P, Pingali MS, Shivalkar S, Varadwaj PK, Sahoo AK, Samanta SK. Bacterial biofilm infections, their resistance to antibiotics therapy and current treatment strategies. Biomedical Materials. 2022 Feb 14;17(2):022003.
52. Anju VT, Busi S, Imchen M, Kumavath R, Mohan MS, Salim SA, Subhaswaraj P, Dyavaiah M. Polymicrobial infections and biofilms: clinical significance and eradication strategies. Antibiotics. 2022 Dec;11(12):1731.
53. Jiang F, Wang J, Ren Z, Hu Y, Wang B, Li M, Yu J, Tang J, Guo G, Cheng Y, Han P. Targeted light-induced immunomodulatory strategy for implant-associated infections via reversing biofilm-mediated immunosuppression. ACS nano. 2024 Feb 22;18(9):6990-7010.
54. Zhang S, Yang H, Wang M, Mantovani D, Yang K, Witte F, Tan L, Yue B, Qu X. Immunomodulatory biomaterials against bacterial infections: Progress, challenges, and future perspectives. The Innovation. 2023 Nov 13;4(6).